期刊论文详细信息
Frontiers in Immunology
Efficacy and safety of Iguratimod in the treatment of Ankylosing Spondylitis: A systematic review and meta-analysis of randomized controlled trials
Immunology
Zhiyong Long1  Liuting Zeng2  Kailin Yang3  Wensa Hao3  Hua Chen3  Ying Deng4  Qi He4  Yuxuan Deng5  Jiapeng Fan6 
[1] Department of Rehabilitation Medicine, Guangzhou Panyu Central Hospital, Guangzhou, China;Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;Hunan University of Chinese Medicine, Changsha, China;People's Hospital of Ningxiang City, Ningxiang, China;Qiqihar Medical University, Qiqihar, China;ZCCC Jinzhu Transportation Construction Co. Ltd., Hangzhou, Zhejiang, China;
关键词: Iguratimod;    ankylosing spondylitis;    systematic review;    meta-analysis;    randomized controlled trial;   
DOI  :  10.3389/fimmu.2023.993860
 received in 2022-07-14, accepted in 2023-01-10,  发布年份 2023
来源: Frontiers
PDF
【 摘 要 】

ObjectiveTo explore the efficacy and safety of Iguratimod (IGU) intervention in the treatment of Ankylosing Spondylitis (AS).MethodsWe used computer to search literature databases, collected randomized controlled trials (RCTs) related to IGU treatment of AS, and searched the relevant literature in each database until Sep. 2022. Two researchers independently carried out literature screening, data extraction, and evaluation and analysis of the risk of bias in the included studies, and then used Rev Man5.3 software for meta-analysis. The protocol is CRD42020220798.ResultsA total of 10 RCTs involves in 622 patients were collected. The statistical analysis showed that IGU can decrease the BASDAI score (SMD -1.62 [-2.20, -1.05], P<0.00001. Quality of evidence: low), the BASFI score (WMD -1.30 [-1.48, -1.12], P<0.00001. Quality of evidence: low) and the VAS (WMD -2.01 [-2.83, -1.19], P<0.00001. Quality of evidence: very low). Meanwhile, the addition of IGU into the conventional therapy would not increase the adverse events (RR 0.65 [0.43, 0.98], P=0.04. Quality of evidence: moderate).ConclusionIGU may be an effective and safe intervention for AS. Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?, identifier CRD42020220798.

【 授权许可】

Unknown   
Copyright © 2023 Long, Deng, He, Yang, Zeng, Hao, Deng, Fan and Chen

【 预 览 】
附件列表
Files Size Format View
RO202310100477817ZK.pdf 4170KB PDF download
  文献评价指标  
  下载次数:24次 浏览次数:0次